Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
ADC ID |
DRG0LVCGV
|
|||||
---|---|---|---|---|---|---|
ADC Name |
Anti-FGFR2 mAb-11725 SMCC-DM1
|
|||||
Synonyms |
Anti-FGFR2-mAb-11725-SMCC-DM1
Click to Show/Hide
|
|||||
Organization |
Novartis AG
|
|||||
Drug Status |
Investigative
|
|||||
Indication |
In total 3 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Colorectal cancer [ICD11:2B91]
Investigative
Gastric cancer [ICD11:2B72]
Investigative
|
|||||
Drug-to-Antibody Ratio |
3.4
|
|||||
Antibody Name |
Anti-FGFR2 mAb 11725
|
Antibody Info | ||||
Antigen Name |
Fibroblast growth factor receptor 2 (FGFR2)
|
Antigen Info | ||||
Payload Name |
Mertansine DM1
|
Payload Info | ||||
Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
Linker Name |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
|
Linker Info |
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Standard Type | Value | Units | Cell Line | Disease Model |
---|---|---|---|---|
Tumor Growth Inhibition value (TGI) |
≈ 77.87
|
%
|
CVCL_0076
|
Gastric adenocarcinoma
|
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 77.87% (Day 31) | Positive FGFR2 expression (FGFR2+++/++) | ||
Method Description |
The total injection volume containing cells in suspension was 200 ul. Mice were enrolled in the first study eight days post implantation with average tumor volume of 192.9 mm3. After being randomly assigned to one of nine groups (n =8/group), mice were administered PBS or a single 3 mg/kg intravenous (i.v,) injection of one antibody drug conjugates.
Click to Show/Hide
|
||||
In Vivo Model | SNU-16 CDX model | ||||
In Vitro Model | Gastric adenocarcinoma | SNU-16 cells | CVCL_0076 |
Revealed Based on the Cell Line Data
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 5.00 nM | Positive FGFR2 expression (FGFR2+++/++) | ||
Method Description |
Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.
Click to Show/Hide
|
||||
In Vitro Model | Gastric adenocarcinoma | SNU-16 cells | CVCL_0076 | ||
Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 5.20 nM | Positive FGFR2 expression (FGFR2+++/++) | ||
Method Description |
Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.
Click to Show/Hide
|
||||
In Vitro Model | Down syndrome | KATO III cells | CVCL_0371 |
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.